219 related articles for article (PubMed ID: 19735093)
61. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
[TBL] [Abstract][Full Text] [Related]
62. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
63. LRRK2 mutations in Basque patients with Parkinson's disease.
Zarranz JJ; Gómez-Esteban JC
Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
[No Abstract] [Full Text] [Related]
64. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
65. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
[TBL] [Abstract][Full Text] [Related]
66. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
[TBL] [Abstract][Full Text] [Related]
67. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
68. Pathogenic mechanisms of neurodegeneration in Parkinson disease.
Mullin S; Schapira AH
Neurol Clin; 2015 Feb; 33(1):1-17. PubMed ID: 25432720
[TBL] [Abstract][Full Text] [Related]
69. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
[TBL] [Abstract][Full Text] [Related]
70. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
Hur EM; Lee BD
Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
[TBL] [Abstract][Full Text] [Related]
71. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
[TBL] [Abstract][Full Text] [Related]
72. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
[TBL] [Abstract][Full Text] [Related]
73. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
74. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.
Smith WW; Pei Z; Jiang H; Moore DJ; Liang Y; West AB; Dawson VL; Dawson TM; Ross CA
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18676-81. PubMed ID: 16352719
[TBL] [Abstract][Full Text] [Related]
75. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
76. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
[TBL] [Abstract][Full Text] [Related]
77. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
[TBL] [Abstract][Full Text] [Related]
78. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain.
Mata IF; Hutter CM; González-Fernández MC; de Pancorbo MM; Lezcano E; Huerta C; Blazquez M; Ribacoba R; Guisasola LM; Salvador C; Gómez-Esteban JC; Zarranz JJ; Infante J; Jankovic J; Deng H; Edwards KL; Alvarez V; Zabetian CP
Neurogenetics; 2009 Oct; 10(4):347-53. PubMed ID: 19308469
[TBL] [Abstract][Full Text] [Related]
79. [Pathogenesis of Parkinson's disease through LRRK2 mutation].
Ohta E; Obata F
Seikagaku; 2014 Feb; 86(1):92-7. PubMed ID: 24693706
[No Abstract] [Full Text] [Related]
80. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
Taymans JM; Cookson MR
Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
